ArticleHaematologica2021

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).

Stephan Stilgenbauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.